Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company focused on first-in-class critical care products and holds a majority interest in Citius Oncology, Inc. News about CTXR often centers on regulatory milestones, clinical progress, and financing activities that support the development and commercialization of its therapies.
Recent company communications emphasize the FDA approval of LYMPHIR (denileukin diftitox-cxdl) for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy, and the subsequent U.S. commercial launch executed by Citius Oncology. CTXR news also highlights the late-stage status of Mino-Lok, a catheter lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief, along with completed pivotal and Phase 2b trials.
Investors following CTXR can expect updates on capital raises such as registered direct offerings and warrant issuances, which the company states are intended to fund the commercial launch of LYMPHIR, regulatory and milestone payments, and broader development initiatives. Filings and press releases also describe ongoing engagement with the FDA regarding next steps for Mino-Lok and Halo-Lido.
This news feed aggregates press releases, regulatory disclosures, and other public announcements related to Citius Pharmaceuticals and its majority-owned oncology subsidiary. For those tracking CTXR, it provides a centralized view of developments across oncology, critical care, clinical trials, and corporate finance. Regular review of this page can help readers monitor how Citius Pharmaceuticals advances its portfolio and supports the commercialization of LYMPHIR through Citius Oncology.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that its CEO, Myron Holubiak, will be featured on TD Ameritrade Network's The Watch List on June 30, 2020, at 1:20 PM ET. The show will involve discussions on market-moving topics with industry experts. Holubiak has a strong background in pharmaceutical management, previously serving as president of Roche Laboratories. Citius focuses on critical care pharmaceutical products, including therapies for acute respiratory distress syndrome (ARDS), which affects many COVID-19 patients annually.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that the FDA has provided feedback on its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) aimed at treating acute respiratory distress syndrome (ARDS) in COVID-19 patients. The FDA suggested that Citius could apply for fast track designation and outlined the chemistry, manufacturing, and control (CMC) requirements necessary for upcoming trials. The company plans to initiate an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP) following the FDA's guidance.
Citius Pharmaceuticals (Nasdaq: CTXR) announced that CEO Myron Holubiak will present at the Life Sciences Investor Forum on June 25, 2020, at 11:00 AM ET. The presentation will provide updates on the Company’s ongoing Phase 3 trial for Mino-Lok® and the potential licensing of a novel stem cell therapy for ARDS in COVID-19 patients. Investors can participate and ask questions during the event, which will also be available via archived webcast.